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Summary
 
TECK (thymus-expressed chemokine), a recently described CC chemokine expressed in thymus
and small intestine, was found to mediate chemotaxis of human G protein–coupled receptor
GPR-9-6/L1.2 transfectants. This activity was blocked by anti–GPR-9-6 monoclonal anti-
body (mAb) 3C3. GPR-9-6 is expressed on a subset of memory 
 
a
 
4
 
b
 
7
 
high
 
 intestinal trafficking
CD4 and CD8 lymphocytes. In addition, all intestinal lamina propria and intraepithelial lym-
phocytes express GPR-9-6. In contrast, GPR-9-6 is not displayed on cutaneous lymphocyte
antigen–positive (CLA
 
1
 
) memory CD4 and CD8 lymphocytes, which traffic to skin inflamma-
 
tory sites, or on other systemic 
 
a
 
4
 
b
 
7
 
2
 
CLA
 
2
 
 memory CD4/CD8 lymphocytes. The majority of
thymocytes also express GPR-9-6, but natural killer cells, monocytes, eosinophils, basophils,
and neutrophils are GPR-9-6 negative. Transcripts of GPR-9-6 and TECK are present in both
small intestine and thymus. Importantly, the expression profile of GPR-9-6 correlates with migra-
tion to TECK of blood T lymphocytes and thymocytes. As migration of these cells is blocked
by anti–GPR-9-6 mAb 3C3, we conclude that GPR-9-6 is the principal chemokine receptor for
TECK. In agreement with the nomenclature rules for chemokine receptors, we propose the desig-
nation CCR-9 for GPR-9-6. The selective expression of TECK and GPR-9-6 in thymus and
small intestine implies a dual role for GPR-9-6/CCR-9, both in T cell development and the
mucosal immune response.
Key words: chemokine • 
 
a
 
4
 
b
 
7 • cutaneous lymphocyte antigen • memory • intestinal
 
C
 
hemokines are a large and growing family of nearly 40
6–14-kD (nonglycosylated) heparin binding proteins
that mediate a wide range of biological functions (1). The
chemokines are divided into four families based on the po-
sition of four cysteine residues that form two disulfide bonds.
Chemokine receptors are currently divided into four fami-
lies based on the type of chemokine they bind, although no
clear structural differences have been identified that distin-
guish the receptor subfamilies (2). There are also a number
of “orphan” receptors with significant sequence similarity
to chemokine receptors whose agonists and functions have
yet to be defined. Chemokines play a vital role in leuko-
cyte adhesion and extravasation. In various in vitro assays,
chemokines support the chemotaxis or transendothelial mi-
gration of leukocytes (1), while in vivo injection (3) or over-
expression of chemokines (4) results in leukocyte accumu-
lation at the site of chemokine expression. Antagonists of
chemokines prevent leukocyte trafficking (5) and have
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beneficial effects in several acute and chronic inflammatory
models (6, 7). Chemokines also modulate angiogenesis (8),
hematopoiesis (1), and T lymphocyte activation (9, 10), and
several act as coreceptors with CD4 for entry of M-tropic
and T-tropic HIV-1 (11, 12).
Subsets of CD4 lymphocytes can be defined based on
their expression of adhesion molecules CD62L, CD49d,
cutaneous lymphocyte antigen (CLA),
 
1
 
 and 
 
a
 
4
 
b
 
7, which
mediate lymphocyte trafficking to different physiological
sites (13). For example, CLA
 
1
 
 memory CD4 lymphocytes
are thought to traffic to the skin (14), whereas the mutually
exclusive subset of 
 
a
 
4
 
b
 
7
 
1
 
 memory CD4 lymphocytes traf-
fics to intestinal sites (15). Leukocyte adhesion to endothe-
lium is thought to involve several overlapping steps of roll-
ing, activation, and arrest, in which exposure of rolling
leukocytes to factors expressed at the site of adhesion acti-
vates leukocytes and upregulates integrin-mediated adhe-
sion. As a result of this interaction, leukocytes arrest on the
endothelium (5, 16). Leukocyte activation and upregula-
tion of integrin molecules occur via a pertussis toxin–sensi-
tive mechanism that is thought to involve chemokine re-
ceptors (8, 16, 17). A growing body of evidence indicates
that leukocyte subsets will also be defined by the expression
of chemokine receptors required to traffic to various physi-
ological sites (18).
To date, several chemokine receptors have been shown
to subdivide memory CD4 lymphocytes. CXC chemokine
receptor (CXCR)3, CC chemokine receptor (CCR)2, and
CCR5 (19–21) are all expressed on subsets of memory
CD4 lymphocytes, whereas certain chemokines act prefer-
entially on naive T lymphocytes (8, 22). Further, several
chemokines that interact with these receptors are expressed
in inflammatory sites and LNs (23, 24). In addition, in vitro–
derived Th1 lymphocyte lines selectively express CXCR3
and CCR5, whereas Th2 lymphocyte lines selectively ex-
press CCR3, CCR4, and CCR8 (25–29). Interestingly, in
some cases the chemokines that bind to these respective
chemokine receptors, such as macrophage-derived chemo-
kine (MDC) for CCR4 and IFN-
 
g
 
–inducible 10-kD pro-
tein (IP-10) for CXCR3, are induced by cytokines associ-
ated with a Th1 or Th2 environment (28, 30).
Based on the assumption that the expression pattern of
chemokine receptors on lymphocytes will prove informa-
tive of their role in leukocyte trafficking, we have prepared
mAbs to orphan chemokine receptors to determine which
subsets of leukocytes express these receptors. In this way,
we hope to better understand the role these orphan
chemokine receptors play in leukocyte trafficking. One such
orphan chemokine receptor, human G protein–coupled re-
ceptor GPR-9-6, is described here. Based on the selective
expression of GPR-9-6 on intestinal homing T lympho-
cytes and resident intestinal intraepithelial lymphocytes
(IELs) and lamina propria lymphocytes (LPLs), we propose
that the receptor will play an important role in T lympho-
cyte trafficking to mucosal sites and in T lymphocyte de-
velopment.
 
Materials and Methods
 
Purification of Cell Populations.
 
Human peripheral blood was
collected in 10% (vol/vol) 0.1 M EDTA, layered onto 1-Step
Polymorphs gradient (Nycomed Pharma) and centrifuged at 400 
 
g
 
for 30 min at room temperature. Neutrophil and mononuclear
cell layers were collected, resuspended in Dulbecco’s PBS (DPBS)
without calcium and magnesium (GIBCO BRL), and centri-
fuged for 15 min at 
 
z
 
750 
 
g
 
. Red blood cells were lysed in the
neutrophil fraction by resuspending the pellet in E-Lyse (Cardinal
Associates) for 5 min on ice. Both cell fractions were washed two
times with ice-cold DPBS. The mononuclear cells were allowed
to adhere to protein-coated plastic for 2–3 h, and nonadherent
cells were gently washed off the plate. After an additional 12 h,
the nonadherent dendritic cells were washed off the plate and de-
pleted of B lymphocytes and T lymphocytes with anti-CD19 and
anti-CD2 Dynabeads (5 beads per cell; Dynal). The remaining
cells were cultured in 50 ng/ml GM-CSF, 40 ng/ml IL-4 DMEM,
and 10% FCS plus additives for 7 d to generate immature DCs,
and in some cases 24 h additional culture in 10 ng/ml LPS was
used to mature the dendritic cells. CD4, CD8, CD14, CD56,
and CD19 populations were purified from mononuclear cells
with the relevant microbeads (Miltenyi Biotec) using 20 
 
m
 
l of
beads for 10
 
7
 
 mononuclear cells in PBS, 1% BSA, 5 mM EDTA
at 5 
 
3
 
 10
 
7
 
 cells/ml for 30 min at 4
 
8
 
C. They were then pelleted,
resuspended in PBS with 1% BSA and 5 mM EDTA at 5 
 
3
 
 10
 
7
 
cells/ml, and passed over a VS column (Miltenyi Biotec) in a
magnetic field to remove nontagged cells. Cells were removed by
forcing 20 ml of PBS with 1% BSA and 5 mM EDTA over the VS
column, outside the magnetic field.
Human small intestine LPLs and IELs were isolated from pa-
tients undergoing gastric bypass surgery for morbid obesity as de-
scribed previously (31). IEL preparations were on average 80%
CD3
 
1
 
, 70% CD8
 
1
 
, 5% CD4
 
1
 
, whereas LPL preparations were
85% CD3
 
1
 
, 40% CD8
 
1
 
, 45% CD4
 
1
 
, consistent with previous
analysis (31). All human subject protocols were approved by the
Human Resources Committee at the Robert Wood Johnson
Medical School, Brigham and Women’s Hospital, or Massachu-
setts General Hospital.
 
Antibodies and Reagents.
 
Anti-CD4, -CD8, -CD14, -CD19,
-CD49d, -CD56, -CD62L, -CLA, -CD45RA, and -CD45RO
dye-linked mAbs for immunofluorescence studies were all obtained
from PharMingen, while anti-
 
a
 
E–FITC was obtained from
Coulter Pharmaceuticals. Anti-CCR4 mAb (2B10) was generated
in the laboratory to CCR4/L1.2 transfectants. OKT3, an anti–
human CD3 mAb, was obtained from American Type Culture
Collection, and anti–human CD28 mAb was purchased from
Becton Dickinson. IP-10, eotaxin-1, B cell–attracting chemokine 1
(BCL-1), IL-8, IFN-inducible T cell 
 
a
 
 chemoattractant (I-TAC),
regulated on activation, normal T cell expressed and secreted pro-
tein (RANTES), fractalkine, leukotactin, liver-expressed chemo-
kine (LEC), eotaxin-3, CK
 
a
 
2, macrophage inflammatory protein
 
1
 
Abbreviations used in this paper:
 
 CLA, cutaneous lymphocyte–associated
antigen; G3PDH, glyceraldehyde 3-phosphate dehydrogenase; GPR,
human G protein–coupled receptor; HEV, high endothelial venule; IEL,
intraepithelial lymphocyte; IP-10, IFN-
 
g
 
–inducible 10-kD protein;
I-TAC, IFN-inducible T cell 
 
a
 
 chemoattractant; LPL, lamina propria
lymphocyte; MCP, monocyte chemoattractant protein; MDC, macro-
phage-derived chemokine; MIG, monokine induced by IFN-
 
g
 
; MIP,
macrophage inflammatory protein; RANTES, regulated upon activation,
normal T cell expressed and secreted protein; SDF, stromal cell–derived
factor; TARC, thymus and activation-regulated chemokine; TECK, thy-
mus-expressed chemokine. 
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(MIP)-1
 
a
 
, monocyte chemoattractant protein (MCP)-1, MIP-4,
I-309, and MDC were synthesized at LeukoSite, Inc., by f-moc
chemistry (433A automated peptide synthesizer; Perkin-Elmer
Biosystems). These chemokines were purified and folded as de-
scribed previously (32). For biotinylated thymus-expressed cyto-
kine (TECK), the chemokine domain of TECK was synthesized
(TECK 24–99). Lys 99 was derivitized during the synthesis with
an aminocapropyl-biotin moiety. A COOH-terminal glycine was
added for synthesis convenience. The TECK chemokine domain
had the same potency as full-length TECK for chemotaxis of
GPR-9-6/L1.2 transfectants (data not shown). All other recom-
binant chemokines were obtained from either PeproTech or
R&D Systems. The human endothelial cell line ECV304 was
purchased from American Type Culture Collection. All cyto-
kines were obtained from R&D Systems.
 
Generation of Anti–GPR-9-6 mAbs.
 
A peptide consisting of the
NH
 
2
 
 terminus of GPR-9-6 was generated by American Peptide
Company having the sequence NH
 
2
 
-MADDYGSESTSSMEDY-
VNFNFTDFYC. BALB/c mice were immunized intraperito-
neally with 10 
 
m
 
g each of GPR-9-6 peptide/KLH conjugate
prepared in complete Freund’s adjuvant (CFA) at day 1, IFA at
day 20, and PBS at day 40. At day 60, the mice were boosted
with 10 
 
m
 
g of GPR-9-6 peptide/KLH in PBS, and after 4 d the
spleens were removed and fused to SP2/0 myeloma cells (Ameri-
can Type Culture Collection). Fusions were screened by ELISA
with plates coated with GPR-9-6 peptide. Hybridomas produc-
ing anti–GPR-9-6 mAbs were checked for reactivity with GPR-
9-6 transfectants and subcloned for further characterization.
 
Preparation of Chronically Activated Th1 and Th2 Lymphocytes.
 
As described previously (33), 6-well
 
 
 
Falcon plates were coated
overnight with 10 
 
m
 
g/ml anti-CD28 and 2 
 
m
 
g/ml OKT3, then
washed twice with PBS. Umbilical cord blood CD4 lymphocytes
(Poietic Systems) were cultured at 10
 
5
 
–10
 
6
 
 cells/ml in DMEM
with 10% FCS and IL-2 (4 ng/ml). IL-12 (5 ng/ml) and anti–IL-4
(1 
 
m
 
g/ml) were used to direct to Th1, while IL-4 (5 ng/ml) and
anti–IFN-
 
g
 
 (1 
 
m
 
g/ml) were used to direct to Th2. After 4–5 d,
the activated Th1 and Th2 lymphocytes were washed once in
DMEM and cultured for 4–7 d in DMEM with 10% FCS and
IL-2 (1 ng/ml). After this, the activated Th1 and Th2 lympho-
cytes were restimulated for 5 d with anti-CD28/OKT3 and cy-
tokines as described above, but with the addition of anti-CD95L
(1 
 
m
 
g/ml) to prevent apoptosis. After 4–5 d, the Th1 and Th2
lymphocytes were washed and then cultured again with IL-2 for
4 d. Activated Th1 and Th2 lymphocytes were maintained in this
way for a maximum of three cycles. Direction of the Th1 and
Th2 lines was confirmed by intracellular cytokine staining and
ELISAs for IL-4 and IFN-
 
g
 
.
 
ECV304 Transmigration and Chemotaxis Assays.
 
3-
 
m
 
M pore di-
ameter Transwell inserts were generally used, with the exception
of the bulk migration experiments for the phenotyping of mi-
grated cells, in which 5-
 
m
 
M inserts were used. The cells under
study were washed once in RPMI and resuspended at 4 
 
3
 
 10
 
6
 
cells/ml for Th1/Th2 lymphocytes, cell lines, and transfectants,
and at 10
 
7 
 
cells/ml for resting CD4 lymphocytes, in RPMI with
0.5% heat-shock antigen (HSA) and 10 mM Hepes. An aliquot of
200 
 
m
 
l of cell suspension (input of 8 
 
3
 
 10
 
5
 
 and 2 
 
3 
 
10
 
6
 
 cells, re-
spectively) was added to each insert. Chemokine in 500–600 
 
m
 
l
of RPMI with 0.5% HSA and 10 mM Hepes was added to the
lower well. After 2–4 h, the inserts were removed and the num-
ber of cells which had migrated through the insert to the lower
well was counted for 30–60 s on a Becton Dickinson FACScan™
with the gates set to acquire the cells of interest. Using this tech-
nique, 100% migration would be 25,000 cells for Th1/Th2 cells
 
and 75,000 cells for resting CD4 lymphocytes, where this num-
ber represents the cells in the lower well counted on the FAC-
Scan™ over 30–60 s. In all cases, the data points were the result
of duplicate wells, with the mean value shown and the error bars
representing the sample standard deviation.
To determine the migration of lymphocyte subsets, the num-
ber of cells in each subtype was determined by multi-color FAC-
Scan™ analysis for the starting population of each chemotactic
assay (34). The number of cells belonging to the same subtype
was determined in the migrated population, and the percentage
of migration was determined from these two numbers. Eight
wells were used for each treatment and pooled for FACScan™
analysis.
As it has been demonstrated previously that most chemokine
receptors couple to the G
 
i
 
 class of G proteins, we wanted to de-
termine if GPR-9-6 also couples to the G
 
i
 
 isoform. Pertussis
toxin was used to block G
 
i
 
-mediated cellular responses. 2 
 
3
 
 10
 
6
 
cells/ml in prewarmed RPMI plus 10% FCS were incubated
with pertussis toxin (GIBCO BRL) at a final concentration of
100 ng/ml for 2 h at 37
 
8
 
C, washed twice with medium, and re-
suspended in chemotaxis medium. Migration was assayed as de-
scribed above.
 
Immunofluorescence Staining.
 
Cells were resuspended at 10
 
7
 
cells/ml in FACS
 
®
 
 buffer (PBS with 5% FCS, 0.1% azide, and
10% human serum to block Fc receptors), and primary mAb was
added. After 20 min, the cells were washed twice in FACS
 
®
 
buffer, and F(ab)
 
2
 
 anti–mouse IgG–PE (absorbed against human
Ig) was added. After 20 min, the cells were washed twice in
FACS
 
®
 
 buffer and then blocked in 10% mouse serum before the
second mAb directly linked to a fluorochrome was added. After
20 min, the cells were washed three times in FACS
 
®
 
 buffer and
analyzed. Throughout the staining, the cells were kept on ice.
We used an IgG
 
2b
 
 isotype control followed by F(ab)
 
2
 
 anti–mouse
IgG–PE as a negative control, and isotype control staining always
fell below 10 FL1 or FL2 units.
 
Binding Assay with Biotinylated TECK.
 
4 
 
3
 
 10
 
5
 
 cells in 25 
 
m
 
l
of PBS with 10% rabbit serum, 1% FCS, and 0.1% sodium azide
(assay buffer) were preincubated with either assay buffer (no
treatment), 1,000 nM TECK/MCP-1, or 50 
 
m
 
g/ml 3C3/IgG
 
2b
 
for 30 min. 25 ml of biotinylated TECK at a final concentration
ranging up to 100 nM was then added, and after 1 h, the cells
were washed twice with 200 ml of wash buffer (PBS with 1% FCS
and 0.1% azide) and resuspended in 25 ml of Wallac Em-labeled
streptavidin diluted 1:400 in assay buffer. After 30 min at room
temperature, the cells were washed in wash buffer and transferred
to a 96-well solid white nonspecific binding plate (3600; Corn-
ing) and, after spinning to remove supernatant, 200 ml of Wallac
Enhancement Solution was added. The fluorescence was counted
on a multilabel counter (model 1420; Wallac) at 340/613 nm and
reported in relative fluorescence units (RFUs).
Calcium Mobilization with Molt-4 Cells. 107 cells/ml in DPBS
were labeled for 30 min with Fura-2 AM (Molecular Probes) at
2 mM, washed three times in DPBS, and resuspended at 106 cells/ml
in DPBS containing 1 mM CaCl2, 0.5 mM MgCl2, 10 mM Hepes
(pH 7.2), and 5.5 mM glucose. Chemokine was then added as in-
dicated in the figure legend, and the calcium flux was measured
on a fluorimeter using 10% NP-40 and 10 mM EGTA to estab-
lish the maximum and minimum Ca21 mobilized.
Recombinant DNA Methods. Plasmid DNA was isolated using
Genomic tips as recommended by the manufacturer (Qiagen).
DNA ligations, restriction endonuclease digestions, and gel elec-
trophoresis were performed as described previously (35). DNA
purification through agarose gel extraction was performed using1244 GPR-9-6 Is Expressed on Intestinal Homing T Cells and Binds TECK
the QIAEXII Gel Extraction kit as recommended by the manu-
facturer (Qiagen). Plasmid DNA was introduced into Escherichia
coli by chemical transformation (GIBCO BRL). Enzymes were
purchased from New England Biolabs, GIBCO BRL, or Boeh-
ringer Mannheim. RNA was isolated from frozen tissues or cells
using either the standard guanidinium isothiocyanate method
(35) or the RNeasy kit as recommended (Qiagen). DNA se-
quencing was performed by MacroMolecular Resources (Colo-
rado State University, Fort Collins, CO) using an ABI DyeRho-
damine Terminator cycle sequencing kit and an ABI Prism DNA
Sequencer (model 377; Perkin-Elmer Applied Biosystems) ac-
cording to the manufacturer’s specifications. Sequences were ana-
lyzed using SeqMan (DNASTAR). Primers were synthesized by
MacroMolecular Resources or by Operon Technologies, Inc.
PCR. Primers were designed for use in the PCR to amplify
the coding region of GPR-9-6 based on the nucleotide sequence
deposited in EMBL/GenBank/DDBJ (accession no. U45982).
BamHI and XbaI sites were incorporated into primer pair
BAZ201 59-TCGAAGGGATCCCTAACATGGCTGATGAC-
TATGGC-39 and BAZ202 59-AAGAAGTCTAGAACCCCT-
CAGAGGGAGAGTGCTCC-39 for directional cloning (bold,
coding sequence; italic, enzyme site). 5 mg of total human ge-
nomic DNA (Clontech) was used as the template in the Pfu PCR
cycles, with 60 mM Tris-HCl (pH 9.5), 1.5 mM MgCl2, 100
pmol primers, 200 mM dNTP, and 5 U PfuI polymerase (Invitro-
gen) in 100 ml volume. The cycle parameters were an initial melt
at 958C for 2 min, then 35 cycles: 958C, 30 s; 558C, 30 s; 728C,
2 min 15 s, followed by a final extension of 728C, 7 min in a DNA
thermal cycler (Perkin-Elmer Corp.).
Primers were designed to amplify the complete coding region
of TECK (sequence data available from EMBL/GenBank/DDBJ
under accession no. U86358) based on the published nucleotide
sequence. HindIII and XbaI sites were incorporated into the
primer pairs for directional cloning. BAZ203 59-TCGAAGAAG-
CTTATGAACCTGTGGCTCCTG-39 and BAZ204 59-AAG-
AAGTCTAGATCACAGTCCTGAATTAGC-39 were used to
amplify TECK (bold, coding sequence; italic, enzyme site). 5 mg
of human thymus RNA was reverse transcribed with oligo(dT)
in 20 ml volume. The cDNA was mixed with 200 mM dNTP,
100 pmol primers, 60 mM Tris-HCl (pH 9.5), 1.5 mM MgCl2, and
10 U AmpliTaq in 50 ml volume. The cycle parameters were an
initial melt at 958C for 2 min, then 35 cycles: 958C, 30 s; 558C,
30 s; 728C, 1 min, followed by a final extension of 728C, 7 min.
The human thymus was obtained from Boston Children’s Hospi-
tal (Boston, MA).
Reverse transcription (RT)-PCR amplifying TECK (BAZ203,
BAZ204) and GPR-9-6 (BAZ201, BAZ202) was performed using
equal amounts (0.5 ng) of cDNA template from thymus, small in-
testine, colon, and brain, as well as 5 mg genomic DNA (Clontech).
The RNA used to prepare the cDNA template was triple oligo(dT)
column purified. The same conditions and PCR profile were used
as the AmpliTaq PCR cycle described above, except that 30 cycles
were performed. Amplification with glyceraldehyde 3-phosphate
dehydrogenase (G3PDH) primers (Clontech) was used to dem-
onstrate equivalence of template. Amplification with G3PDH
intron B specific primers (BAZ205 59-TCCCCTGCCAGCCT-
AGCGTTGACC-39 and BAZ206 59-CCCCACTATGCCAC-
CCCAGGAATG-39) was used to confirm the absence of contam-
inating genomic DNA in the Clontech cDNAs.
After agarose gel electrophoresis, the PCR products were vi-
sualized in the presence of ethidium bromide with an ultraviolet
light source. DNA fragments of predicted size (z450 bp for
TECK and z1 kb for GPR-9-6) were isolated and cloned into
pBluescript II KS1 (Stratagene) and pcDNA3 (Invitrogen) for
sequence analysis and further manipulation.
Expression Vector Construction and Generation of a GPR-9-6–express-
ing Stable Cell Line. The coding region of GPR-9-6 was ampli-
Figure 1. The mAb 3C3 binds
to GPR-9-6 transfectants. (A)
GPR-9-6/L1.2 transfectants were
stained with mAb 3C3 (black
profile), an IgG2b control mAb
(white), and an anti-CCR6 mAb
(gray). (B) CCR6/L1.2 transfec-
tants were stained with the same
anti-CCR6 (gray), 3C3 (black),
and IgG2b (white) mAbs (n 5 2).
Table I. Distribution of GPR-9-6 on Cell Lines
Cell line GPR-9-6 CXCR4 Cell Chemotaxis
Molt-4 11 T 1
Molt-13 11 T 1
CEM 21 T 2
Peer 21 T 2
Hut-78 21 TN D
PM1 21 TN D
SKW3 21 TN D
Jurkat 21 TN D
Ramos 21 BN D
Raji 21 BN D
JY 21 B 2
THP1 22 MN D
U937 21 M 2
HL60 21 /2 NN D
KG1 21 ML ND
KU812 22 ML ND
EOL 22 Eos ND
Several cell lines representing T lymphocytes (T), B lymphocytes (B),
neutrophils (N), eosinophils (Eos), monocytes (M), and myelogenous
leukemia cells (ML) were stained with mAb 3C3, as well as with an
anti-CXCR4 control mAb since most cell lines express CXCR4. The
cell lines that expressed GPR-9-6, as well as several negative lines, were
examined for their chemotaxis to 150 nM TECK.1245 Zabel et al.
fied by PCR and directionally cloned into the BamHI/XbaI sites
of pcDNA3. Transfectants were generated in the murine pre-B
lymphoma cell line L1.2 as described previously (36), and main-
tained in RPMI 1640 supplemented with 10% FCS, 2 mM
l-glutamine, 50 U/ml penicillin/streptomycin, 0.55 mM b-mer-
captoethanol, 10 mM Hepes, 1 mM sodium pyruvate, and 1 mg/
ml G418 (Geneticin) for selection. The transfectants were then
stained by mAbs with reactivity against the GPR-9-6 peptide (see
below) and analyzed by FACScan™ to confirm surface expres-
sion of GPR-9-6, then cloned by limiting dilution. Transfected
cells were treated with 5 mM n-butyric acid for 24 h before ex-
perimentation.
Northern Blot Analysis. Northern blots were either purchased
from Clontech or prepared as follows: total RNA was separated
by electrophoresis on 1.2% formaldehyde agarose gels and trans-
ferred to a nylon membrane (Hybond-N1; Amersham Pharma-
cia Biotech) by the capillary method as described previously (34)
and cross-linked using a Stratalinker (Stratagene). Full-length gel-
purified TECK, GPR-9-6, and b-actin (Clontech) were radio-
labeled using High Prime reagents (Boehringer Mannheim) ac-
cording to the manufacturer’s specifications. Hybridizations were
performed in ExpressHyb Solution (Clontech) using the manu-
facturer’s suggested protocol. Length of autoradiography expo-
sure is described in appropriate figure legends.
Results
An mAb Raised against GPR-9-6 Selectively Reacts with
GPR-9-6 Transfectants. Due to its close phylogenetic asso-
ciation with other known leukocyte chemokine receptors
such as CCR6 and CCR7, we cloned GPR-9-6 by PCR,
using primers designed from the deposited EMBL/Gen-
Bank/DDBJ sequence. GPR-9-6/L1.2 transfectants were
prepared and stained with mAbs raised against the first 30
amino acids of the NH2 terminus of GPR-9-6 coupled to
KLH. One mAb, designated 3C3, reacted with GPR-9-6/
L1.2 transfectants but not with parental L1.2 cells. 3C3 was
found to have an IgG2b isotype. In cross-reactivity studies,
3C3 did not cross-react with CCR1–7 or CXCR1–4 trans-
fectants. We show the data for CCR6 here, as it is one of
the more closely related chemokine receptors to GPR-9-6
(Fig. 1). Also, the NH2-terminal peptide of GPR-9-6 blocked
the binding of mAb 3C3 to GPR-9-6 transfectants (data not
shown), further validating the specificity of this mAb.
GPR-9-6 Is Expressed on Molt T Cell Lines, Subsets of CD4,
CD8, and B Lymphocytes in Peripheral Blood, and Thymocytes.
mAb 3C3 was used to identify surface expression of GPR-
9-6 on various cell lines and primary cells. Out of a panel
Figure 2. GPR-9-6 is expressed on subsets
of CD4 and CD8 lymphocytes as well as on
most thymocytes. The mAb 3C3 was used in
two-color studies on mononuclear cells along
with a F(ab)2 anti–mouse IgG–PE second
stage and anti-CD4–FITC, anti-CD8–FITC,
anti-CD19–FITC, anti-CCR3–FITC, and
anti-CD56–Cychrome mAbs. For thymo-
cytes, two-color studies were performed with
3C3 and anti-TCR–Cychrome. The per-
centage of cells falling within each quadrant is
shown at the upper right. Staining with an
isotype control IgG2b mAb followed by F(ab)2
anti–mouse IgG–PE was performed and gave
FL2 values ,10 U (n 5 6).
Figure 3. GPR-9-6 is expressed on b7highCLA2
memory CD4 lymphocytes. Mononuclear cells
were stained in three-color experiments using anti-
CD4–Tricolor to gate on CD4 lymphocytes. The cells
were also stained with anti–GPR-9-6 mAb 3C3
followed by F(ab)2 anti–mouse IgG–PE or –FITC
to study GPR-9-6 expression on subsets defined
with dye-linked mAbs: anti-aE–FITC (HML1),
anti-b7–PE (Fib504), anti-CD49d–PE (HP2/1),
anti-CLA–FITC (HECA 452), anti-CD45RO–
FITC (UCLH1), and anti-CD62L–PE (Dreg 56).
Staining with an isotype control IgG2b mAb fol-
lowed by F(ab)2 anti–mouse IgG–PE/FITC was
performed and gave FL1/FL2 values ,10 U. The
percentage of cells falling within each quadrant is
shown in the upper right (n 5 5).1246 GPR-9-6 Is Expressed on Intestinal Homing T Cells and Binds TECK
of cell lines, only Molt-4 and Molt-13 T cell lines ex-
pressed GPR-9-6 (Table I). In addition, GPR-9-6 was ex-
pressed on a small subset of CD4 lymphocytes (2–4%) as
well as on a small subset of CD8 lymphocytes (Fig. 2). A
subset of B lymphocytes also expressed GPR-9-6. Mono-
cytes, basophils, eosinophils, neutrophils, immature and ma-
ture dendritic cells, and NK cells did not express GPR-9-6
(Fig. 2, and data not shown). GPR-9-6 was expressed on
.90% of thymocytes that expressed all levels of TCR, al-
though a small subset of TCRhighGPR-9-62 thymocytes was
evident. In three-color experiments, GPR-9-6 was found
on the majority of CD41, CD81, and CD41CD81 thymo-
cytes and on z50% of immature CD42CD82 thymocytes
(data not shown).
The CD4 and CD8 Lymphocyte Subsets That Express GPR-
9-6 Also Express High Levels of Mucosal Lymphoid Homing Re-
ceptor a4b7 but Not Skin Homing Receptor CLA. To deter-
mine which subset of CD4 and CD8 lymphocytes expressed
GPR-9-6, three-color flow cytometry was performed (Fig. 3).
The CD4 lymphocytes that expressed GPR-9-6 were mainly
of memory phenotype, and those cells that expressed the
highest levels of GPR-9-6 were all of memory phenotype.
Interestingly, almost all of the GPR-9-61 CD4 lympho-
cytes expressed high levels of the a4b7 integrin, which is ex-
pressed on gut-trafficking T lymphocytes, and lacked expres-
sion of CLA, which mediates T lymphocyte trafficking to
inflamed skin. The subset of memory CD4 lymphocytes
defined by expression of aE and CD62L was also subdivided
into GPR-9-6 positive and negative subpopulations.
Upon analysis over multiple donors, a subset of CD4 lym-
phocytes that expressed low levels of GPR-9-6 was evident.
This subset was more apparent when we used four-color
analysis and gated on memory and naive CD4 lymphocytes,
as defined by CD45RO expression (Fig. 4). Expression of
GPR-9-6 on memory CD4 lymphocytes was more than
threefold higher than that on naive CD4 lymphocytes, as
shown in Fig. 4 where the ratio of the mean fluorescent in-
tensities of GPR-9-6 on naive and memory CD4 lympho-
cytes approaches 3.5 when an anti–mouse IgG–PE second
stage was used. GPR-9-6low CD4 lymphocytes expressed
CD62L, a homing receptor involved in lymphocyte traffick-
ing to organized lymphoid tissues via high endothelial
venules (HEVs), and low levels of b7. In contrast, the major-
ity of the GPR-9-6high memory CD4 lymphocyte subset did
not express CD62L, but expressed high levels of b7.
Like GPR-9-61 CD4 lymphocytes, GPR-9-61 CD8 lym-
phocytes also expressed high levels of b7 and were CLA2
(Fig. 5). CD45RO and CD45RA are not as extensively used
as memory markers for CD8 lymphocytes. However, GPR-
9-6 was expressed on CD45RAlow CD8 lymphocytes. Also,
as observed for CD4 lymphocytes, a subset of GPR-9-6low
cells was evident that was CD45RAhighCD62L1, whereas
GPR-9-6high CD8 lymphocytes were CD62L2. Finally, the
majority of aE1 CD8 lymphocytes expressed GPR-9-6,
whereas GPR-9-6low CD8 lymphocytes were mainly aE2.
Further, aE1 CD8 lymphocytes that did not express GPR-
9-6 expressed lower levels of aE than aE1GPR-9-61 CD8
lymphocytes.
GPR-9-6 Is Expressed on Intestinal IELs and LPLs. The
selective expression of GPR-9-6 on a subset of intestinal
trafficking CD4 and CD8 blood lymphocytes suggests that
the receptor may be involved in lymphocyte homing to the
intestine. Therefore, we examined the expression of GPR-
9-6 on T lymphocytes isolated from the small intestine.
Flow cytometric analysis revealed that GPR-9-6 was ex-
pressed on all intestinal IELs and LPLs (Fig. 6). Compared
with GPR-9-6 expression on PBL lymphocytes, the chemo-
kine receptor was found to be significantly enriched on T
lymphocytes in intestinal tissue.
Activation of Umbilical CD4 Lymphocytes to Th1 or Th2 Effec-
tor T Lymphocytes Did Not Induce Expression of GPR-9-6,
Whereas TCR Cross-linking Resulted in Downregulation of GPR-
9-6 on T Lymphocytes. As GPR-9-6 was expressed on a
Figure 4. Characterization of GPR-9-6 expression on memory and naive
CD4 lymphocytes: Mononuclear cells were stained in four-color experi-
ments using anti-CD4–TC and anti-CD45RO–allophycocyanin to gate on
memory and naive CD4 lymphocytes. The cells were also stained with anti–
GPR-9-6 mAb 3C3 followed by F(ab)2 anti–mouse IgG–PE or –FITC to
study GPR-9-6 expression on subsets defined with dye-linked mAbs: anti-
aE–FITC (HML1), anti-b7–PE (Fib504), anti-CD49d–PE (HP2/1), anti-
CLA–FITC (HECA 452), and anti-CD62L–PE (Dreg 56). Staining with an
isotype control IgG2b mAb followed by F(ab)2 anti–mouse IgG–PE/FITC
was performed and gave FL1/FL2 values ,10 U. The percentage of cells
falling within each quadrant is shown in the upper right. To directly com-
pare the levels of GPR-9-6 on naive and memory subsets defined by expres-
sion of GPR-9-6, we show the ratio of the mean fluorescence intensity for
memory/naive subset for the relevant quadrants (Q) (n 5 3).1247 Zabel et al.
subset of memory T lymphocytes, we attempted to induce
expression of GPR-9-6 on umbilical CD4 lymphocytes by
activation in the presence of directing cytokines to generate
Th1 and Th2 lymphocytes. Although the Th1 and Th2
lymphocyte lines showed the appropriate differential pro-
duction of IL-4, IL-13, and IFN-g upon activation (data
not shown), chronic activation of these cells in the pres-
ence of IL-12 or IL-4 to generate Th1 or Th2 lymphocytes
failed to induce the expression of GPR-9-6 (Fig. 7 B). Fur-
ther, chronic activation of umbilical CD4 lymphocytes in
the presence of IL-1–13, IL-15, IL-17, IL-18, and TGF-b
did not induce expression of GPR-9-6 (data not shown).
As expected, CXCR3 was upregulated selectively on Th1
lymphocytes (Fig. 7 A). Interestingly, activation of T lym-
phocytes through cross-linking of TCR resulted in tran-
sient downregulation of GPR-9-6 expression (Fig. 6 C), with
reexpression of GPR-9-6 observed upon removal of the
TCR stimulation and culture in IL-2. This effect was not
specific to the chemokine receptor GPR-9-6, as the other
chemokine receptors expressed by T lymphocytes that we
examined (CCR5 and CCR6) were also transiently down-
regulated upon TCR cross-linking (Fig. 7 D). Expression
by T lymphocytes of other CD molecules such as CD29,
CD44, and CD49d was unaffected by T lymphocyte acti-
Figure 5. GPR-9-6 is expressed on b7high
CLA2 memory CD8 lymphocytes and pre-
dominantly aE1 CD8 lymphocytes. Mono-
nuclear cells were stained in three-color ex-
periments using anti-CD8–TC to gate CD8
lymphocytes. The cells were also stained with
anti–GPR-9-6 mAb 3C3 followed by F(ab)2
anti–mouse IgG–PE or –FITC to study
GPR-9-6 expression on subsets defined with
dye-linked mAbs: anti-aE–FITC (HML1),
anti-b7–PE (Fib504), anti-CD49d–PE
(HP2/1), anti-CLA–FITC (HECA 452), anti-
CD45RA–FITC, and anti-CD62L–PE (Dreg
56). Staining with an isotype control IgG2b
mAb followed by F(ab)2 anti–mouse IgG–PE/
FITC was performed and gave values ,10 U.
The percentage of cells falling within each
quadrant is shown in the upper right (n 5 4).
Figure 6. GPR-9-6 is expressed on intestinal IELs and LPLs. Freshly
isolated LPLs and IELs were stained with anti–GPR-9-6 mAb 3C3 (gray
profile) or with a mouse IgG2b control mAb (white). PBLs were also
stained as an internal control from a separate donor. Similar results were
obtained from four different mucosal cell populations.
Figure 7. Modulation of GPR-9-6 on lymphocytes by cytokines and
upon T lymphocyte activation. (A and B) Chronically activated Th1
(dark line) and Th2 lymphocytes (thin line) at second stage activation
were stained with anti-CXCR3 and anti–GPR-9-6 mAb 3C3. Staining
of Th1 lymphocytes with an isotype control IgG2b mAb served as a neg-
ative control (dashed line). (C and D) Mononuclear cells were acti-
vated with plate-bound anti-TCR mAb OKT3 for 4 d followed by ex-
pansion with IL-2 at 5 ng/ml. Aliquots of cells were stained at the
indicated times with anti–GPR-9-6, anti-CCR5, and anti-CCR6 to deter-
mine the effect of T lymphocyte activation upon expression of GPR-9-6
(C) and other chemokine receptors (D), using an anti-CD3 mAb to di-
rectly label the T lymphocytes (n 5 2).1248 GPR-9-6 Is Expressed on Intestinal Homing T Cells and Binds TECK
vation (data not shown).
The GPR-9-6 Chemokine Receptor Specifically Interacts with
TECK and Mediates Thymocyte and CD4 Lymphocyte Chemo-
taxis. From a panel of chemokines including MCP-1–4,
MIP-1ab, MIP-3ab, eotaxin-1–3, RANTES, I-309, thymus
and activation-regulated chemokine (TARC), MDC, liver-
expressed chemokine (LEC), CKa2, secondary lymphoid-
tissue chemokine (SLC), human CC chemokine 1, fractal-
kine, lymphotactin, monokine induced by IFN-g (MIG),
IP-10, I-TAC, B cell–attracting chemokine 1 (BCL-1), IL-8,
gro-abc, leukotactin, stromal cell–derived factor (SDF)-
1a/b, MIP-3, and MIP-4, only TECK induced chemotaxis
of GPR-9-6/L1.2 transfectants (Fig. 8 A, and data not
shown). TECK-mediated chemotaxis of L1.2/GPR-9-6
transfectants was inhibited by anti–GPR-9-6 mAb 3C3
(Fig. 8 B), while pretreatment of the transfectants with per-
tussis toxin also inhibited migration to TECK (Fig. 8 B).
The observation that pertussis toxin abolished TECK-medi-
ated transfectant chemotaxis indicates that chemokine re-
ceptor GPR-9-6 couples to the Gi class of G proteins.
TECK did not act on any of the other transfectants tested
(CCR1,2,4–7 and CXCR1–4), with the exception of
CCR3/L1.2 transfectants, for which high concentrations
of TECK were weakly chemotactic (data not shown). Also
in examining our panel of cell lines, we found that only
GPR-9-61 Molt-4 and Molt-13 cell lines migrated to TECK
(Table I). Migration of Molt-4 and Molt-13 cells to TECK
was blocked by anti–GPR-9-6 mAb 3C3 (data not shown).
Primary thymocytes were also chemotaxic for TECK in
a dose-dependent manner (Fig. 8 C), and this migration
was blocked by anti–GPR-9-6 mAb 3C3, but not by an
IgG2b control (Fig. 8 D). In contrast, anti–GPR-9-6 did
not block thymocyte migration to SDF-1a, which binds to
CXCR4 on thymocytes (Fig. 8 D). We also found that a
small subset of CD4 lymphocytes (,0.5% of input) mi-
grated to TECK and that this chemotaxis was blocked by
Figure 8. GPR-9-6 is a che-
mokine receptor for TECK. (A)
GPR-9-6 transfectants were ex-
amined for chemotactic responses
to various concentrations of
TECK  and I-TAC ranging from
10 to 1,000 nM. (B) The effect of
anti–GPR-9-6 mAb 3C3 and
pertussis toxin (PTX) on the mi-
gration was examined. All mAb
treatments were for 10 min at 48C
before the migration assay. (C)
Thymocytes were examined for
their chemotaxis to various con-
centrations of TECK. (D) The ef-
fect of anti–GPR-9-6 mAb 3C3
and an IgG2b control on TECK-
and SDF-1a–induced thymocyte
migration was also examined. The
effect of anti–GPR-9-6 mAb and
anti-CCR4 mAb 2B10 on the
chemotaxis of CD4 lymphocytes
to TECK (E) and TARC (F) was
also tested (n 5 2).1249 Zabel et al.
anti–GPR-9-6 mAb 3C3, but not by an anti-CCR4 mAb,
2B10. In contrast, 3C3 mAb had no effect on TARC-
induced CD4 lymphocyte chemotaxis (Fig. 8, E and F). In
our experiments, TECK was not chemotactic for other to-
tal cell populations in peripheral blood, including B lym-
phocytes, CD8 lymphocytes, neutrophils, monocytes, and
eosinophils (data not shown).
The  a4b7highCLA2CD45RA2 CD4 and aE1a4b71
CD45RAlow/2 CD8 Lymphocytes Migrate to TECK. In our
preliminary chemotaxis studies, we were able to demon-
strate that TECK induced significant but very low levels of
migration of peripheral blood CD4 lymphocytes. This re-
flects the low percentage of CD4 lymphocytes that express
GPR-9-6 and the background migration of the total popu-
lation of CD4 lymphocytes. As GPR-9-6 was expressed at
high levels mainly on small subsets of memory b7high CD4
and CD8 lymphocytes, we examined the phenotype of
the memory CD4 and CD8 lymphocytes that migrate to
TECK using multi-color FACScan™ analysis with anti-
CD4, anti-CD8, anti-CD45RA, anti-CLA, anti-a4b7 mAb
Act1, and anti-aE (Fig. 9). Act1 is an mAb that recognizes
a combinatorial epitope on a4b7 and therefore can be used
to specifically examine expression of this integrin on leuko-
cytes. The gut-homing a4b71CLA2 memory CD4 lympho-
cytes were enriched in the migrated population, whereas
skin-homing a4b72CLA1 memory CD4 lymphocytes and
a4b72CLA2 memory CD4 lymphocytes were not (Fig.
10 A). Therefore, the memory CD4 lymphocytes that mi-
grate to TECK are contained in the gut-homing a4b71
CLA2 memory CD4 lymphocyte subpopulation. For the
CD8 lymphocytes, the anti-CD45RA mAb was used to
define the memory CD8 lymphocytes as CD45RAlow/2. As
GPR-9-6 was expressed at high levels on CD8 lympho-
cytes that express high levels of aE or b7, we analyzed the
expression of aE and a4b7 on the migrated CD8 lympho-
cytes. Higher random migration of CD45RAlow/2 CD8
lymphocytes was evident, but the cells responsive to TECK
were greatly enriched in the aE1a4b71CD45RAlow/2 CD8
lymphocyte subset (Fig. 9 B).
TECK Induces Ca21 Flux in GPR-9-61 Cell Line Molt-4.
In addition to its ability to induce cell migration, TECK
also induced a more robust Ca21 flux in Molt-4 cells than
was observed with SDF-1a, whose receptor (CXCR4) was
also expressed by Molt-4 cells (Fig. 10). MDC did not in-
duce Ca21 flux in Molt-4 cells, which do not express
CCR4, the receptor for MDC.
TECK Binds to GPR-9-61 Molt-4 Cells and Blocks the
Binding of Anti–GPR-9-6 mAb 3C3 to GPR-9-61 Cells.
As TECK was chemotactic for GPR-9-6–expressing cells, we
evaluated whether TECK binds to GPR-9-6. Although tyro-
sine-iodinated TECK did not bind to GPR-9-61 Molt-4
Figure 9. TECK preferentially attracts gut-homing memory CD4 lym-
phocytes and aE1a4b71CD45RAlow/2 CD8 lymphocytes. Mononuclear
cells from two donors were allowed to migrate to 1 mM TECK (black
bars) and also to medium (white). (A) The starting and migrated popula-
tions were analyzed by multiparameter flow cytometry to determine the
percentages of skin-homing CLA1a4b72, gut-homing memory
CLA2a4b71, and other systemic CLA2a4b72 memory CD4 lympho-
cytes in the starting and migrated populations. (B) The starting and mi-
grated populations were analyzed to determine the percentage of
aE1a4b71,  aE2a4b71, and aE2a4b72CD45RAlow/2 CD8 lympho-
cytes in the starting and migrated populations. With knowledge of the to-
tal input and the number of migrated cells, these values are expressed as
percentage of input (n 5 3).
Figure 10. TECK induces Ca21 flux in GPR-9-61 Molt-4 cells. The
GPR-9-6–expressing cell line Molt-4 was loaded with Ca21 dye Fura-2
and then tested for the ability to mobilize Ca21 in response to 150 nM
TECK, 100 nM SDF-1a, and 100 nM MDC (n 5 2).1250 GPR-9-6 Is Expressed on Intestinal Homing T Cells and Binds TECK
cells, biotinylated TECK bound in a dose-dependent and
saturable manner. In contrast, biotinylated TECK did not
bind to GPR-9-62 CEM cells (Fig. 11 A). Binding of bio-
tinylated TECK to Molt-4 cells was inhibited by either 500
nM TECK or by the anti–GPR-9-6 mAb 3C3, but not by
either 500 nM MCP-1 or an IgG2b control mAb (Fig. 11 B).
Preincubation of GPR-9-6 transfectants, CD4 cells, and B
lymphocytes with TECK inhibited the staining with anti–
GPR-9-6 mAb 3C3, whereas MDC had no effect (Fig.
12). Although these experiments were performed at 48C
and with azide, in the absence of a nonblocking anti–
GPR-9-6 mAb, we cannot be certain of whether these re-
sults reflect either blocking or downmodulation of the
chemokine receptor. However, these data do demonstrate
that the staining pattern we observe with mAb 3C3 is not
due to nonspecific binding of mAb 3C3 to lymphocytes.
Tissue Distribution of TECK and GPR-9-6 Transcripts.
Due to the expression of GPR-9-6 on mucosal homing
lymphocytes, we examined the distribution of TECK and
GPR-9-6 transcripts in lymphoid and mucosal tissues (Fig.
13). TECK was selectively expressed in thymus and small
intestine (Fig. 13 A). GPR-9-6 was expressed at high levels
in thymus and weakly in spleen and PBLs (Fig. 13 B). Al-
though we could not detect GPR-9-6 transcripts by North-
ern blot analysis in small intestine, we were able to detect
GPR-9-6 message in small intestine and thymus using the
more sensitive technique of RT-PCR (Fig. 13 C). Message
for either gene was not detected in brain or colon. Also as
predicted from our expression data on cell lines with mAb
3C3, GPR-9-6 was expressed by Molt-13 cells (and Molt-4
cells, data not shown) but not in GPR-9-62 JY, KU812, and
EOL cells. In additional Northern blot analysis, TECK and
GPR-9-6 were not detected in Th1, Th2, or T regulatory
type 1 lymphocytes, LAK (lymphokine-activated NK) cells,
monocytes, CD34-derived dendritic cells, monocyte-derived
dendritic cells, astrocytes, high umbilical vein endothelial
cells, or pulmonary vein endothelial cells (data not shown).
Discussion
Selective expression of adhesion molecules on T lym-
phocyte subsets mediates trafficking to distinct physiologic
locations, such as peripheral LNs (37), intestinal sites (15,
38), and different tissue inflammatory sites (13, 39–41). It is
thought that specific chemokine receptors expressed on
these lymphocyte subsets interact with chemokines expressed
in these areas to mediate leukocyte activation, arrest, and
transendothelial migration. Therefore, it is possible that
lymphocyte subsets defined by their expression of certain
adhesion molecules may also express known, orphan, or as
yet undiscovered chemokine receptors that will be impor-
tant in trafficking of the lymphocytes into these sites. Our
work describes one such chemokine receptor that is selec-
tively expressed at high levels on thymocytes, gut-homing
memory CD4 and CD8 lymphocytes, and intestinal mu-
cosal lymphocytes.
GPR-9-6 was originally chosen as a potentially interesting
orphan chemokine receptor due to its strong phylogenetic
linkage with other known chemokine receptors including
CCR6 and CCR7. To evaluate its function, we generated
GPR-9-6 transfectants and performed studies to determine
which chemokines induced chemotaxis of GPR-9-61 cells.
Out of all the chemokines tested, only TECK (42) acted as
a chemoattractant for GPR-9-6/L1.2 transfectants. In con-
trast, TECK did not induce chemotaxis of L1.2 cells trans-
fected with CCR1,2,4–7 or 9 or CXCR1–4 or 5. Although
TECK also induced chemotaxis of CCR3/L1.2 transfec-
tants, this was a relatively weak effect, inducing only 20%
of the chemotactic mobility observed with eotaxin-1.
Thus, TECK appears to have a restricted effect. In addition,
in examining tumor cell lines for chemotaxis to TECK,
GPR-9-6 expression directly correlated with chemotaxis.
TECK-mediated chemotaxis of GPR-9-61 transfectants,
tumor cell lines, thymocytes, and CD4 lymphocytes was
inhibited by anti–GPR-9-6 mAb 3C3. Thus, GPR-9-6
appears to represent the main chemokine receptor through
which TECK acts on these cell populations, and to be a se-
lective receptor for TECK. Like other chemokine receptors,
the chemotaxis of GPR-9-6/L1.2 transfectants to TECK ap-
pears to be mediated exclusively through Gi signaling, as
treatment with pertussis toxin abolishes transfectant migra-
tion to TECK.
In dose–response curves, 150 nM TECK resulted in opti-
mal chemotaxis of GPR-9-6–expressing transfectants. This
falls into the range of 1 nM to 1 mM at which other leuko-
cyte chemokines are active. However, as a recombinant
Figure 11. Biotinylated TECK binds to
Molt-4 cells. (A) Molt-4 and CEM cells were
tested for their ability to bind to biotinylated
TECK used at concentrations of 100, 50, 25,
12.5, 6.25, and 3.125 nM. (B) We also ex-
amined the effect of preincubating the cells
for 10 min with 500 nM TECK, 500 nM
MCP-1, and 50 ug/ml anti–GPR-9-6 mAb
3C3 or an IgG2b mAb on the binding of
Molt-4 and CEM cells with biotinylated
TECK (n 5 2).1251 Zabel et al.
TECK produced by E. coli (PeproTech) was used for these
studies, it remains possible that proper posttranslational mod-
ifications of the chemokine may not have occurred and that
the recombinant TECK has a somewhat different activity
than naturally produced TECK. In addition, further cleavage
of TECK by factors outside the cell in vivo could generate
more active fragments, as is the case for CKb8 (43). Thus,
the actual dose–response curve in vivo may differ from that
determined using the reagents currently available.
In published reports and in our own analysis, TECK is
prominently expressed in the thymus. Therefore, we evalu-
ated whether GPR-9-6 is expressed on thymocytes. In-
deed, GPR-9-6 mRNA was detected prominently in thy-
mic tissue based on Northern blot analysis. In addition,
based on two- and three-color flow cytometry, GPR-9-6
polypeptide was expressed on the cell surface of the major-
ity of thymocytes bearing all levels of TCR. Thus, GPR-9-6
is apparently expressed at all stages of T lymphocyte devel-
opment. However, there was a small subpopulation of
TCRhigh thymocytes that lacked GPR-9-6 expression. Fur-
ther, most naive peripheral blood T lymphocytes derived
from adults were either GPR-9-62 or expressed low levels
of GPR-9-6 based on FACS® analysis. Thus, it appears
likely that GPR-9-6 is downregulated near the time of thy-
mocyte exit to the periphery. The expression of both
GPR-9-6 and its ligand in the thymus demonstrates that
TECK and GPR-9-6 probably interact in vivo as well as in
vitro. This chemokine receptor–ligand pair is likely to play
a role in thymocyte development, perhaps through effects
on thymocyte localization or activation.
TECK was originally cloned from fetal intestine (42),
and our Northern blot analysis revealed abundant TECK
mRNA expressed in small intestine tissue derived from
adults. Thus, it seemed possible that TECK might also
function to recruit circulating lymphocytes to the intestine.
To evaluate this possibility, we determined the expression
of GPR-9-6 on PBLs. Although most PBLs lacked cell sur-
face GPR-9-6, there was a small subset of peripheral T
lymphocytes that was GPR-9-61. In three-color experi-
ments, GPR-9-6 was found predominantly on memory
CD4 and CD8 lymphocytes that coexpressed high levels
of the gut-homing receptor, a4b7. However, in the case
of CD8 lymphocytes, we observed a greater correlation of
GPR-9-6 and aE expression. GPR-9-61 T lymphocytes
also lack expression of CLA, which is consistent with a
possible role of TECK in gut T lymphocyte localization.
Furthermore, TECK induced chemotaxis of a small subset
of CD4 lymphocytes that were enriched in the b71 mem-
ory CD4/CD8 subset that expresses GPR-9-6. In addition,
although we did not detect chemotaxis of total CD8 lym-
phocytes to TECK, we were able to identify a subset of
aE1a4b71CD45RAlow/2 CD8 lymphocytes that was en-
riched in the population of cells that migrated in response
to TECK, suggesting that TECK induced migration of this
CD8 lymphocyte subset. Thus, the GPR-9-6 expressed on
memory CD4 and CD8 lymphocytes is functional to in-
duce chemotaxis. In contrast to GPR-9-6 expression,
CCR4 is expressed on CLA1 or CLA2 a4b72 circulating
memory CD4 lymphocytes (13, 38, 44), but not on a4b7high
cells. Thus, CCR4 and GPR-9-6 may define nonoverlap-
ping subsets of memory CD4 lymphocytes that traffic to
different sites.
GPR-9-6 was also expressed on a substantial proportion
of B lymphocytes in peripheral blood, both with 3C3 and
also with a second anti–GPR-9-6 mAb (data not shown),
and staining of B lymphocytes with 3C3 was blocked by
TECK. However, B lymphocytes were not chemotaxic for
Figure 12. TECK blocks the binding of mAb 3C3 to GPR-9-6 on
transfectants and lymphocytes. (A) L1.2/GPR-9-6 transfectants were pre-
incubated with various concentrations of TECK or MDC on ice in PBS
with 5% FCS, 10% human serum, and 0.2% azide for 10 min before the
addition of mAb 3C3. (B) Mononuclear cells were treated in a similar
manner but with either 500 nM MDC or 500 nM TECK. Cells were
then stained as described in Materials and Methods (n 5 2).1252 GPR-9-6 Is Expressed on Intestinal Homing T Cells and Binds TECK
TECK. This may reflect either the reduced motility of these
cells or the failure of GPR-9-6 to mediate chemotaxis of B
lymphocytes, as observed for CCR1 on neutrophils. Al-
though the evidence suggests that a subset of B lympho-
cytes that express GPR-9-6 does exist, the function of
GPR-9-6 on these cells is not clear.
If GPR-9-6 plays a role in the localization of T lympho-
cytes to the intestine, its expression might be enhanced on
T lymphocytes in this tissue site. Indeed, while we did not
detect GPR-9-6 transcripts in small intestine using rela-
tively less sensitive Northern blot analysis, GPR-9-6 tran-
scripts were detected in small intestinal tissue via RT-PCR.
Further, flow cytometry revealed GPR-9-6 expression on
almost all intestinal IELs and lamina propria T lymphocytes
isolated from normal individuals undergoing gastric bypass
surgery. Thus, expression of GPR-9-6 was greatly enriched
on CD4 and CD8 lymphocytes present in intestinal tissue
compared with its expression on peripheral T lymphocytes.
The expression of TECK in small intestine and of GPR-
9-6 on a subset of intestinal trafficking T lymphocytes indi-
cates that TECK may play a role in the trafficking of GPR-
9-61 CD4 and CD8 lymphocytes to intestinal sites. It is
possible that expression of TECK by postcapillary venules in
the lamina propria or by Peyer’s patch HEVs may activate
GPR-9-61 T lymphocytes and lead to leukocyte arrest via
a4b7–mucosal addressin cell adhesion molecule 1 (MAd-
CAM-1) interactions, and thus in the selective extravasa-
tion of memory intestinal T lymphocytes within the intes-
tine. Additionally, as the majority of resident intestinal IELs
and LPLs express GPR-9-6, TECK may play a role in their
Figure 13. Tissue distribution
of TECK and GPR-9-6. (A)
TECK hybridizations: 32P-labeled
TECK DNA was used to probe
multitissue Northern blot filters
(2  mg poly-A RNA per lane, 24-h
exposure; Clontech). (B) GPR-
9-6 hybridizations: 32P-labeled
GPR-9-6 DNA was used to
probe the same filters as in A as
well as a multi-cell line Northern
blot filter (72-h exposure). (C)
Equivalent amounts (0.5 ng) of
primary cDNA (Clontech) from
colon, small intestine, brain, and
thymus, as well as 500 ng ge-
nomic DNA were amplified in
PCR (30 cycles) using GPR-9-6
and TECK primers. G3PDH
primers and G3PDH intron B
primers were used as controls.1253 Zabel et al.
localization within intestinal tissue or effector action at
these sites. For example, it is possible that selective expres-
sion of TECK by epithelial or other cells in the small intes-
tine could direct GPR-9-61 T lymphocyte migration af-
ter the cells have crossed the endothelium and entered the
intestinal tissue. Finally, although the majority of CD4
lymphocytes that express GPR-9-6 are memory cells, a
small subset of naive phenotype CD4 lymphocytes also ex-
presses GPR-9-6, albeit at lower levels. These may repre-
sent T lymphocytes that have recently emigrated from the
thymus. Alternatively, a subpopulation of naive T lympho-
cytes may traffic to sites of TECK expression in the small
intestine. It is of interest that while most GPR-9-6high
memory CD4 lymphocytes do not express CD62L, GPR-
9-6low naive CD4 lymphocytes do express CD62L. High
levels of expression of a4b7 (such as those observed on
memory CD4 lymphocytes) are thought to be sufficient to
mediate lymphocyte tethering and rolling via MAdCAM-1
on lamina propria as well as HEVs in Peyer’s patches.
However, low levels of expression of this integrin (such
as those observed on naive CD4 lymphocytes) are not
thought to be sufficient (16, 17). It is possible that the co-
expression of CD62L and low levels of a4b7 on GPR-9-6low
naive CD4 lymphocyte could allow initiation of rolling on
Peyer’s patch HEVs, with resulting arrest after lymphocyte
activation and LFA-1 and a4b7 avidity upregulation.
We postulate that factors present in the mucosal environ-
ment lead to the induction of GPR-9-6 on T lymphocytes
as well as TECK expression. Cytokines present in Th1/Th2
environments, at least in vitro, induce expression of certain
chemokine receptors, such as CCR4 on Th2 and CXCR3
on Th1 lymphocytes, as well as the production of the
chemokines that bind these receptors (25–30). However,
these conditions did not upregulate GPR-9-6 expression on
T lymphocytes. Also, our attempts to induce expression of
GPR-9-6 on activated umbilical CD4 lymphocytes with cy-
tokines IL-1–13, IL-15, IL-17, IL-18, and TGF-b, previ-
ously shown to induce aE on T lymphocytes (45), failed to
identify a cytokine that upregulates GPR-9-6 expression.
Therefore, there must be an as yet undefined mechanism by
which GPR-9-6 expression is controlled on T lymphocytes.
In addition to studying the effect of cytokines on
chemokine receptor expression, we wanted to determine if
GPR-9-6 was modulated after T lymphocyte stimulation
via antigen receptor cross-linking. Upon activation via TCR
cross-linking, expression of GPR-9-6 is downregulated, as
are other chemokine receptors such as CCR5, CCR6, and
CXCR4 (46). When the TCR is disengaged, GPR-9-6 is
reexpressed by the T lymphocyte. As TCR cross-linking
mimics antigen presentation, we conclude that upon TCR
cross-linking via appropriate MHC class II–peptide com-
plexes expressed by APCs, T lymphocytes will downregu-
late chemokine receptors such as GPR-9-6. By this
method, T lymphocytes will be held in association with ei-
ther dendritic cells or B lymphocytes until the relevant sig-
nals involved in antigen presentation or T–B cognate inter-
actions have occurred.
In summary, we have shown that orphan chemokine re-
ceptor GPR-9-6 is expressed on the majority of thymo-
cytes, intestinal IELs, LPLs, and on discrete subsets of T
lymphocytes that traffic to intestinal sites. The CC chemo-
kine TECK interacts with GPR-9-6 and mediates the
chemotaxis of cells bearing this receptor. Based on the
demonstration that GPR-9-6 induces chemotaxis of cell
populations in a dose-dependent fashion in response to a
chemokine, we propose to name this orphan chemokine
receptor CCR-9. These findings, together with the selec-
tive expression of TECK and GPR-9-6 in thymus and
small intestine, imply a dual role for GPR-9-6, both in T
cell development and in the intestinal immune response.
While this manuscript was in submission, Zaballos et al.
(47) reported that TECK acts as a chemoattractant for
HEK293/human GPR-9-6 transfectants as well as for the
Molt-4 cell line.
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